Perrigo (NYSE:PRGO) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Perrigo Company plc (NYSE:PRGO) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $11.43 and traded as high as $13.76. Perrigo shares last traded at $13.6630, with a volume of 1,828,665 shares.

Analyst Upgrades and Downgrades

PRGO has been the subject of several analyst reports. Wall Street Zen upgraded Perrigo from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings upgraded Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $19.33.

Perrigo Stock Up 0.5%

The company’s 50-day moving average is $12.33 and its 200 day moving average is $11.43. The stock has a market capitalization of $1.90 billion, a PE ratio of -1.09, a price-to-earnings-growth ratio of 1.56 and a beta of 0.59. The company has a current ratio of 2.32, a quick ratio of 1.32 and a debt-to-equity ratio of 1.31.

Perrigo (NYSE:PRGO) last released its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.11. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. Perrigo’s revenue was down 3.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.06) EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, analysts anticipate that Perrigo Company plc will post 2.18 EPS for the current year.

Perrigo Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 28th will be paid a $0.29 dividend. The ex-dividend date is Friday, August 28th. This represents a $1.16 dividend on an annualized basis and a yield of 8.5%. Perrigo’s dividend payout ratio (DPR) is -9.27%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Amundi lifted its stake in Perrigo by 11.7% in the first quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after acquiring an additional 556 shares during the last quarter. Kestra Investment Management LLC increased its position in shares of Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after purchasing an additional 642 shares during the last quarter. Geneos Wealth Management Inc. increased its position in shares of Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares in the last quarter. Finally, Covestor Ltd raised its holdings in shares of Perrigo by 14.4% in the 4th quarter. Covestor Ltd now owns 8,991 shares of the company’s stock valued at $125,000 after purchasing an additional 1,129 shares in the last quarter. 95.91% of the stock is owned by institutional investors and hedge funds.

About Perrigo

Perrigo Company plc is a global consumer self-care company that develops, manufactures and markets over-the-counter (OTC) products and other nonprescription health and wellness products. Its portfolio spans consumer health categories including pain relief, allergy and cold remedies, digestive health, skin care, oral care, vitamins and supplements, and women’s health.

The company sells products under both its own brands and retailer-owned store brands through pharmacies, supermarkets, mass merchants, e-commerce channels and other outlets.